Immunohistochemistry biomarker TP53 expression predicts the survival of thymomas

Dongliang Bian; Liting Zhao; Xuelin Zhang; Fanzhen Lv; Zhenghong Zhu; Hui Qiu; Huibiao Zhang

doi:10.21037/gs.2020.03.01

Immunohistochemistry biomarker TP53 expression predicts the survival of thymomas

Gland Surg. 2020 Apr;9(2):291-299. doi: 10.21037/gs.2020.03.01.

Authors

Dongliang Bian¹, Liting Zhao¹, Xuelin Zhang¹, Fanzhen Lv¹, Zhenghong Zhu¹, Hui Qiu², Huibiao Zhang¹

Affiliations

¹ Department of Thoracic Surgery, Fudan University Affiliated Huadong Hospital, Shanghai 200040, China.
² Department of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.

Abstract

Background: Thymomas are rare malignancies. Thymectomy is the optimal therapy which could prolong the survival of patients. However, prognostic factors of thymomas are not clear.

Methods: Thymomas patients were enrolled from 2001 to 2016. Clinical and pathological prognostic factors of thymomas were evaluated by univariate and multivariate analyses.

Results: A total number of 98 patients was eligible for this study. All patients were received complete resection (CR). Diagnostic age [elder than the median 60 vs. younger than 60, hazard ratio (HR) =2.325, P=0.027], Masaoka stage (III vs. I, HR =10.756, P<0.001; IV vs. I, HR =6.558, P=0.014), and diabetes mellitus (DM) (with vs. without, HR =0.142, P=0.004) were independent prognostic factors for overall survival (OS). Immunohistochemistry (IHC) biomarker TP53 expression also influenced OS significantly (positive vs. negative, HR =5.157, P=0.018). Furthermore, age (elder than 60 vs. younger than 60, HR =2.980, P=0.022) was independent prognostic factors for recurrence free survival (RFS).

Conclusions: We found that diagnostic age, clinical stages, DM, TP53 expression in IHC, and quality perioperative nursing are prognostic factors in thymomas.

Keywords: TP53; Thymomas; surgery.